Immuron - FY25 global sales exceed projection, up 49% on prior year
Provided By GlobeNewswire
Last update: Jul 17, 2025
Sales Highlights (unaudited):
MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.
Read more at globenewswire.com
